MMR test results in colon cancer after surgery
Part of Cancer, Digestive system clinical trials.
This study looks at the results of MMR/MSI tests in people who had colon cancer surgery. The goal is to see how often these tests show certain patterns, which may help guide treatment decisions in the future.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You had surgery to remove colon cancer (adenocarcinoma), not another type of tumor.
- Your surgery was done between June 1, 2025 and May 31, 2026 at a hospital that treats many colon cancer patients.
- Your tumor was tested for MMR proteins or MSI (microsatellite instability) — these tests help guide treatment.
- You do not have rectal cancer (cancer near the anus).
- Your medical records are complete enough to show your MMR/MSI status.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial uses a simple blood test to look for tiny bits of tumor DNA after colon cancer surgery. If found, it may help doctors catch any remaining cancer early and guide further treatment.
This trial tests whether giving the immunotherapy drug pembrolizumab before surgery can shrink or eliminate colon tumors in people with dMMR/MSI-high cancer, possibly allowing some to avoid surgery. It is for patients whose cancer has not spread.
This trial is studying whether some people with a specific type of advanced colorectal cancer (MSI-H/dMMR) might be able to skip surgery after immunotherapy. Doctors will use a blood test (MRD monitoring) to track the cancer, and then decide whether to keep an eye on it or operate.
This trial tests a new immunotherapy drug (AK104) given before and after surgery for a specific type of colon cancer that is MSI-H or dMMR. The goal is to see if the drug helps shrink the tumor and prevent the cancer from coming back.
This study uses a simple blood test (called MRD) after surgery to see if any tiny bits of cancer DNA are left. It helps doctors decide whether extra chemotherapy is needed or if it can be safely skipped, and it may reduce unnecessary side effects.
This study is looking at whether regular checks of your blood for tiny pieces of cancer DNA (called MRD) can help doctors monitor for the cancer coming back after surgery. It plans to use this information to guide follow-up care.
Hear when a new Colon Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.